OnPAR launched in 2016 in partnership with the National Institutes of Health (NIH). OnPAR has now expanded to accept reviewed, high scoring abstracts from all research investigators globally. In the near future, OnPAR will be enhanced to include:
- un-reviewed ideas
- pharmaceutical assets
- other research based collateral
- clinical trials information
OnPAR is a matchmaking platform where applicants and non-government funders come together. Government, private foundations, private foundations, pharmaceutical companies, venture capital funds, and other funds for biomedical research are part of a funding ecosystem that supports global biomedical research. Their goal is to support research and drug development for the advancement of public health. Over the last decade, these organizations have begun working together to build on their complementary strengths. OnPAR is a new funding paradigm that seeks to build public-private partnerships within the funding ecosystem.
The goal of OnPAR is to match quality biomedical research projects with priority areas of interest of private foundations, pharmaceutical and biotech companies and/or other private biomedical research funders to advance research, discovery, and development that will benefit the world.
The OnPAR fact sheet is available at this link: OnPAR Facts.
For more than 20 years, Leidos Health’s Life Sciences division has supported the full spectrum of biomedical research programs for government and non-government clients through program/portfolio development and evaluation, peer and programmatic review, comprehensive grants management, and marketing and communications. Leidos Health helps to manage programs from initial concept through exploratory basic research, development, and preclinical and clinical phases, up to product manufacturing and launching. Over the past two decades, our doctoral- and master’s-level scientists have been supporting biomedical research programs in the areas of military health and injury, cancer, diabetes, multiple sclerosis, autism, Alzheimer’s, and other diseases. Leidos Health provides subject matter experts for federal funders and other research-focused programs requiring infrastructure, process, and policy support.
For more information on Leidos Health’s Life Sciences capabilities please visit our site: Health/Life-Science
Partners are national and international government funding agencies who work with Leidos to announce OnPAR to their unfunded, high-scoring applicants. The National Institute of Health (NIH), in the United States, is the founding partner. OnPAR personnel are in conversations with other national and international funders to join OnPAR within the next 6 months.
Click on each organization to access their website.
|Australia National Health and Medical Research Council (NHMRC)|
|National Scientific and Technical Research Council (CONICET)|
|Canadian Institutes of Health Research (CIHR)|
|Cancer Research Society|
|Fonds de recherché Sante Quebec|
|National Science Foundation of China (NSFC)|
|European Commission (EU)|
|The World Academy of Sciences (TWAS)|
|Japan Agency for Medical Research and Development (AMED)|
|Japan Society for the Promotion of Science (JSPS)|
|Consejo Nacional de Ciencia y Tecnologia of Mexico (CONACYT)|
|Agency for Science, Technology and Research (A*STAR)|
|South Africa Medical Research Council (SAMRC)|
|Biotechnology and Biological Sciences Research Council|
|Cancer Research UK (CRUK)|
|Medical Research Council (MRC)|
|UK Department of Health / National Institute for Health Research (NIHR)|
|Wellcome Trust (WT)|
World Wide Agencies
|World Health Organization (WHO)|